[1] Taniguchi H,Katano T,Nishida K,et al.Elucidation of the mechanism of suppressed steroidogenesis during androgen deprivation therapy of prostate cancer patients using a mouse model[J].Andrology,2016,4(5):964-971. [2] 裴昕奇.晚期前列腺癌内分泌治疗血清睾酮浓度与疾病进展的关系[J].现代泌尿外科杂志,2017,22(5):339-343. [3] Golla V,Kaplan A L.Testosterone therapy on active surveillance and following definitive treatment for prostate cancer[J].Curr Urol Rep,2017,18(7):49. [4] Shen YC,Kang CH,Chiang PH.Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer[J].Kaohsiung J Med Sci,2016,32(11):567-571. [5] Loughlin K R.The testosterone conundrum: The putative relationship between testosterone levels and prostate cancer[J].Urol Oncol,2016,34(11):481-482. [6] 孙忠全,沈志远.睾酮与前列腺癌研究进展[J].中华男科学杂志,2014,20(8):675-678. [7] Traish A.Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return[J].Investig Clin Urol,2016,57(6):384-400. [8] Uttley L,Whyte S,Gomersall T,et al.Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal[J].Pharmacoeconomics,2017,35(7):717-726. [9] 王峰,方浩.非甾体类雄激素受体拮抗剂的研究进展[J].现代药物与临床,2012,27(2):88-93.
2018, Vol. 35 
